TU4.8 An Analysis of Rectal Cancer Patient Treatment and Outcomes in a large NHS Trust. (9th August 2022)

• Record Type: Journal Article
• Authors: Hamer, Natalie; Hand, Rebecca; Kaur, Japsimar; Thambi, Prem; Wadd, Nicholas; Jha, Madan
• Is Part Of: British journal of surgery. Volume 109(2022)Supplement 5
• Publication Date: 2022-08-09
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1093/bjs/znac248.040
• Languages: English
• ISSNs: 0007-1323

Abstract

Abstract: Introduction: Rectal cancer (RC) is a common cancer in the UK. Treatment options include surgery, chemotherapy, radiotherapy or a combination of these in the form of neoadjuvant or adjuvant treatment. Aim: To analyse the treatment type and outcomes of our RC patients. Methods: We performed an analysis of prospectively collected data on patients diagnosed with RC between Jan-2013 and Dec-2020 in our trust. Details included demographics, histology, staging, treatment and mortality. Twenty patients out of 1202 were excluded due to missing information leaving 1182 for further analysis. Results: 404 patients did not receive resectional surgery due to patient choice (30), inoperability of the tumour (259), or co-morbidity (115). A total of 778 patients were found to have operable disease with TNM staging as follows; Stage1–291, Stage2–231, Stage3–217, Stage4–39. Among them 302 went on to receive neo-adjuvant treatment of which 67 (22.2%) had a complete response to treatment (ypT0). The remaining 476 patients received primary surgery; 268 did not require any additional treatment and 199 went on to have adjuvant chemo/radiotherapy. Nine patients had further intervention due to incomplete resection or disease recurrence. The majority of the tumours were adenocarcinomas (97%). Other types included; malignant melanoma, neuroendocrine tumours, and squamous cell carcinomas. The overall 1-year and 5-year mortality for the group receiving primary surgery were 5.0% and 20.4%. In the neoadjuvant group these were 3.6% and 20.9%. Conclusion: We present data from a large NHS trust demonstrating a multimodal approach which has enabled us to achieve good overall outcomes.